SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection

NCT01962441 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

601

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C

Interventions

DRUG: SOF
DRUG: RBV
DRUG: Peg-IFN

Sponsor

Gilead Sciences